Rapport Therapeutics Inc

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change in long episode frequency is the primary endpoint for Rapport's ongoing Phase 2a proof-of-concept trial in focal epilepsy, with topline data expected in mid-2025 Data from additional studies, including preclinical seizure data and Phase 1 pharmacokinetic and safety trial results, support the potential of RAP-219 as a transformational treatment for patients with focal epilepsy BOSTON and LOS ANGELES, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, presents novel findings on the association between a seizure biomarker used in the Company's proof-of-concept trial for RAP-219 and clinical seizures. The analysis demonstrated a linear relationship between changes in long episode (LE) frequency and clinical seizure frequency and identified the benchmark to predict clinically meaningful seizure reduction.

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows:

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

ChoiceOne Financial Services Inc

Neonode

PureCycle Technologies

Global Self Storage

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Veuillez trouver ci-joint le rapport annuel Pilier 3 au 30 juin 2024 Attachment Rapport semestriel Pilier 3 - 30 juin 2024

Rapport semestriel Pilier 3 - 30 juin 2024

BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced presentations at two upcoming medical conferences: the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress (EEC) in Rome, Italy, September 7-11, 2024, and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta, Ga., September 25-26, 2024.

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences:

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

AMN Healthcare Services

Bristol-Myers

The healthcare industry has been a critical part of the economy for a long time. According to a McKinsey & Company report, the healthcare industry is expected to grow at 7% from 2022 to 2027.

The 3 Best Healthcare Stocks to Buy in August 2024

PACS Group, Inc.

Tempus AI Inc

Global markets are down as fears of an economic downturn triggered a near-term crisis. This is a reminder that corrections can come from most unexpected events.

3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns

Preclinical data on TARPγ8 targeted compound, an analog to Rapport's lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models Preclinical data on TARPγ8 targeted compound, an analog to Rapport's lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Rapport's shares began trading on the Nasdaq Global Market on June 7, 2024, under the ticker symbol “RAPP.” All of the shares of common stock were sold by Rapport.

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Johnson & Johnson

Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.

J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut

Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.

J&J-backed Rapport Therapeutics raises $136 mln in US IPO

BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the pricing of its initial public offering of 8,000,000 shares of its common stock at a public offering price of $17.00 per share. Rapport's shares are expected to begin trading on the Nasdaq Global Market on June 7, 2024 under the ticker symbol “RAPP.” The offering is expected to close on June 10, 2024, subject to the satisfaction of customary closing conditions. In addition, Rapport has granted the underwriters a 30-day option to purchase an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Rapport.

Rapport Therapeutics Announces Pricing of Initial Public Offering

Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their shares amid a rebound in the capital markets.

J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO

Rapport Therapeutics, Inc. has filed for a $100 million IPO to develop treatment candidates for central nervous system and related disorders. The company's lead candidate, RAP-219, is being developed to treat Focal Epilepsy, peripheral nerve pain, and bipolar disorder. Rapport Therapeutics is backed by top-tier life science venture capital firms and has connections to Johnson & Johnson, so the IPO is one to watch.

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

News for Rapport Therapeutics Inc Stock (RAPP)